{"id":"antipsychotic-maintenance","safety":{"commonSideEffects":[{"rate":"10–50% depending on agent","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"10–30%","effect":"Weight gain"},{"rate":"15–25%","effect":"Metabolic syndrome (hyperglycemia, dyslipidemia)"},{"rate":"20–40%","effect":"Prolactin elevation (galactorrhea, sexual dysfunction)"},{"rate":"10–30%","effect":"Sedation"},{"rate":"3–5% per year","effect":"Tardive dyskinesia (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL2103791","moleculeType":"Small molecule","molecularWeight":"351.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antipsychotics antagonize dopamine D2 receptors and often serotonin 5-HT2A receptors, reducing hyperactivity in mesolimbic and mesocortical dopamine pathways that underlie positive symptoms (hallucinations, delusions) and some negative symptoms. Maintenance therapy involves long-term administration—often as depot/long-acting formulations—to sustain symptom control and reduce hospitalization risk in chronic psychotic disorders.","oneSentence":"Antipsychotic maintenance therapy works by blocking dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and prevent relapse in patients with schizophrenia or bipolar disorder.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:23.977Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of schizophrenia"},{"name":"Maintenance treatment of bipolar disorder (manic or mixed episodes)"},{"name":"Prevention of relapse in chronic psychotic disorders"}]},"trialDetails":[{"nctId":"NCT06456983","phase":"NA","title":"Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-02-14","conditions":"Schizophrenia, Treatment Resistant Schizophrenia","enrollment":140},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT07246044","phase":"NA","title":"HD-tDCS for Adolescent Bipolar Depression Targeting S1","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-09-16","conditions":"Adolescent, Bipolar Depression, tDCS","enrollment":100},{"nctId":"NCT07075237","phase":"PHASE4","title":"Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-10","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":"Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":288},{"nctId":"NCT07025590","phase":"NA","title":"Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-04-22","conditions":"Cardiovascular Diseases (CVD), Depression Anxiety Disorder","enrollment":106},{"nctId":"NCT07011953","phase":"EARLY_PHASE1","title":"A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-07-01","conditions":"Schizophrenia, Avolition","enrollment":90},{"nctId":"NCT06754163","phase":"PHASE4","title":"Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients","status":"RECRUITING","sponsor":"St Andrew's Healthcare","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions, Psychiatric Disorders","enrollment":20},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT05667961","phase":"","title":"Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-15","conditions":"Schizophrenia","enrollment":480},{"nctId":"NCT01029769","phase":"NA","title":"Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2009-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":350},{"nctId":"NCT04546178","phase":"NA","title":"Psychotherapy for Psychosis, Adverse Events, and Substance Misuse","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2021-11-15","conditions":"Psychotic Disorders, Stress Disorders, Traumatic, Substance Use","enrollment":19},{"nctId":"NCT05498441","phase":"NA","title":"Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode","status":"UNKNOWN","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2022-04-01","conditions":"Major Depressive Episode","enrollment":120},{"nctId":"NCT05473741","phase":"","title":"Risk of Breakthrough Symptoms With Long-Acting Injectable Medications","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-09","conditions":"Schizophrenia, Schizophrenia Relapse","enrollment":180},{"nctId":"NCT05259631","phase":"PHASE3","title":"Inhalational (Sevoflurane) Versus Intravenous (Propofol) Sedation in Adults With a Moderate Form of ARDS","status":"SUSPENDED","sponsor":"Negovsky Reanimatology Research Institute","startDate":"2022-03-14","conditions":"Acute Respiratory Distress Syndrome","enrollment":310},{"nctId":"NCT03559426","phase":"PHASE4","title":"Research Into Antipsychotic Discontinuation and Reduction Trial","status":"COMPLETED","sponsor":"University College, London","startDate":"2016-03-24","conditions":"Schizophrenia, Schizoaffective Disorder, Delusional Disorder","enrollment":253},{"nctId":"NCT03852706","phase":"NA","title":"EEG-based Neurofeedback for Auditory Verbal Hallucinations (HALFEED)","status":"TERMINATED","sponsor":"University of Dublin, Trinity College","startDate":"2019-03-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT01584466","phase":"NA","title":"Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2014-01","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT03376763","phase":"PHASE4","title":"MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-11-21","conditions":"Schizophrenia, Antipsychotics, Long-Acting Injection","enrollment":201},{"nctId":"NCT03955549","phase":"PHASE3","title":"Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial","status":"COMPLETED","sponsor":"Agiad Psychiatry Hospital","startDate":"2019-05-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":99},{"nctId":"NCT01738698","phase":"PHASE3","title":"Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2012-11-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT01760889","phase":"PHASE3","title":"SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT01760993","phase":"PHASE3","title":"Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT01234298","phase":"PHASE3","title":"SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia","status":"WITHDRAWN","sponsor":"Shire","startDate":"2012-01-27","conditions":"Negative Symptoms of Schizophrenia","enrollment":""},{"nctId":"NCT04898270","phase":"PHASE4","title":"Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2019-12-19","conditions":"Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol","enrollment":30},{"nctId":"NCT04856124","phase":"","title":"Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine","status":"COMPLETED","sponsor":"Psych Atlanta","startDate":"2018-09-01","conditions":"Treatment Resistant Depression","enrollment":10},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT02787135","phase":"NA","title":"Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for Psychosis","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2016-05-01","conditions":"Schizophrenia, Psychotic Disorders, Delusions","enrollment":94},{"nctId":"NCT03090490","phase":"NA","title":"10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-09","conditions":"Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":68},{"nctId":"NCT03643159","phase":"PHASE4","title":"A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-06-28","conditions":"Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder","enrollment":2},{"nctId":"NCT03130465","phase":"","title":"Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia","status":"UNKNOWN","sponsor":"Otsuka Pharmaceutical Europe Ltd","startDate":"2017-07-13","conditions":"Schizophrenia","enrollment":636},{"nctId":"NCT02593058","phase":"NA","title":"Positive Emotions Program for Schizophrenia (PEPS)","status":"COMPLETED","sponsor":"Institut et Haute Ecole de la Santé la Source","startDate":"2016-02-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":80},{"nctId":"NCT03887754","phase":"PHASE2","title":"Therapeutic Issues for Autism","status":"COMPLETED","sponsor":"Minia University","startDate":"2016-01","conditions":"Autism Spectrum Disorder","enrollment":80},{"nctId":"NCT01052714","phase":"NA","title":"Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-09-01","conditions":"Diabetes, Obesity, Weight Gain","enrollment":121},{"nctId":"NCT03248180","phase":"","title":"Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-07-24","conditions":"Psychosis, Remission","enrollment":160},{"nctId":"NCT01731119","phase":"PHASE2","title":"Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":9},{"nctId":"NCT02220504","phase":"NA","title":"3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2004-07","conditions":"Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":68},{"nctId":"NCT00344500","phase":"NA","title":"Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2005-10","conditions":"Diabetes, Obesity, Weight Gain","enrollment":122},{"nctId":"NCT01977300","phase":"PHASE3","title":"Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-01","conditions":"Bipolar I Disorder","enrollment":159},{"nctId":"NCT00790517","phase":"PHASE2","title":"Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2009-06","conditions":"Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders","enrollment":200},{"nctId":"NCT01936220","phase":"NA","title":"Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"1997-09","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01888107","phase":"PHASE3","title":"Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2005-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":347},{"nctId":"NCT00044681","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-10","conditions":"Depressive Disorder, Depressive Disorder, Major, Depression","enrollment":258},{"nctId":"NCT00334035","phase":"PHASE4","title":"Antipsychotic Therapy and First Episode","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2003-08","conditions":"Schizophrenia","enrollment":169},{"nctId":"NCT00253162","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-03","conditions":"Bipolar Disorders, Manic Disorder","enrollment":439},{"nctId":"NCT01066403","phase":"NA","title":"Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2003-10","conditions":"Schizophrenia","enrollment":28},{"nctId":"NCT00926965","phase":"PHASE4","title":"Tardive Dyskinesia and Cognitive Function","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2003-01","conditions":"Tardive Dyskinesia, Neurocognitive Function","enrollment":80},{"nctId":"NCT00081380","phase":"PHASE3","title":"Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-03","conditions":"Bipolar Disorder","enrollment":710},{"nctId":"NCT00654576","phase":"PHASE4","title":"Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Central South University","startDate":"2005-02","conditions":"Schizophrenia","enrollment":1400},{"nctId":"NCT00159081","phase":"PHASE4","title":"One Year Drug Treatment in First-Episode Schizophrenia","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2000-11","conditions":"Schizophrenia","enrollment":159},{"nctId":"NCT00159120","phase":"PHASE4","title":"Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2001-11","conditions":"Schizophrenia, Psychoses","enrollment":71},{"nctId":"NCT00159133","phase":"PHASE4","title":"Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2001-11","conditions":"Schizophrenia, Psychoses","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Antipsychotic Maintenance","genericName":"Antipsychotic Maintenance","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antipsychotic maintenance therapy works by blocking dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and prevent relapse in patients with schizophrenia or bipolar disorder. Used for Maintenance treatment of schizophrenia, Maintenance treatment of bipolar disorder (manic or mixed episodes), Prevention of relapse in chronic psychotic disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}